Episode 71: Cardiogenic Shock Working Group: Patients on Impella 5.5 for more than 14 days

On this episode of JHLT: The Podcast, the Digital Media Editors invite co-lead author Nir Uriel, MD, Director of Advanced Heart Failure and Cardiac Transplantation at New York Presbyterian Hospital and Professor of Medicine at Columbia University.

Dr. Uriel joins to discuss the work of the Cardiogenic Shock Working Group (CSWG) and their recent paper, "Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis."

The discussion explores:

• Why patients on longer duration of MCS had better survival but maintained similar rates of serious adverse events (SAEs)
• Why the study might show fewer SAEs than the literature historically shows
• How temporary MCS devices are selected in clinical settings in patients with cardiogenic shock
• The ongoing and upcoming activities of CSWG

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.